Balance Sheet

Cash Flow Statement

Acquisitions Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Bio-Rad Laboratories (BIO) Long-Term Debt Issuances (2022)

Bio-Rad Laboratories has reported Long-Term Debt Issuances over the past 2 years, most recently at -$20000.0 for Q4 2022.

Quarterly Long-Term Debt Issuances changed N/A to -$20000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$20000.0 through Sep 2023, down 100.0% year-over-year, with the annual reading at $1.2 billion for FY2022, N/A changed from the prior year.
Long-Term Debt Issuances was -$20000.0 for Q4 2022 at Bio-Rad Laboratories, down from $1.2 billion in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $1.2 billion in Q1 2022 and troughed at -$20000.0 in Q4 2022.